Caron Jacobson, MD

Articles by Caron Jacobson, MD

Axi-Cel Demonstrates Efficacy in Non-Hodgkin Lymphoma, Including DLBCL

December 22nd 2020

Caron Jacobson, MD, discusses the survival and response data for axicabtagene ciloleucel from the phase 1/2 ZUMA-1 trial.

Toxicity Profile of CAR T-Cell Therapy Appears Safe in Follicular and Marginal Zone Lymphomas

ByCaron Jacobson, MD

July 6th 2020

Caron Jacobson, MD, discusses the safety findings from the phase 2 ZUMA-5 tidal evaluating axicabtagene ciloleucel in patients with follicular lymphoma and marginal zone lymphoma.

Caron Jacobson, MD

Articles by Caron Jacobson, MD

Axi-Cel Demonstrates Efficacy in Non-Hodgkin Lymphoma, Including DLBCL

Toxicity Profile of CAR T-Cell Therapy Appears Safe in Follicular and Marginal Zone Lymphomas

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma